The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular the present disclosure relates to carbene compounds particularly platinum containing carbenes and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum containing ca...

The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds nanoparticles and compositions comprising said f...

The present invention relates to ligand targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group which is connected to a linker wich in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is conne...

The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically the conjugate comprises a targeting ligand and a molecule of interest e.g. a therapeutic agent. The targeting ligand and the molecule ...

The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular the present disclosure relates to platinum based compounds comprising platinum moiety linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said...

The present disclosure relates generally to supramolecular combinatorial therapeutics compositions comprising same and uses thereof. In particular the present disclosure provides hydrophobic taxane lipid covalent conjugates which create supramolecular assembly for example within lipid bilayer providing an extra stab...

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I) compositions and formulations comprising the same methods processes and uses thereof. In particular the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathwa...